Literature DB >> 14724833

Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon.

Takanobu Kato1, Tomoko Date, Michiko Miyamoto, Akihiro Furusaka, Katsutoshi Tokushige, Masashi Mizokami, Takaji Wakita.   

Abstract

BACKGROUND & AIMS: Although the hepatitis C virus (HCV) subgenomic replicon system has been widely used in the study of HCV, this system is available only for a few related genotypes. To develop a new replicon system, the genotype 2a clone JFH-1 was isolated from a patient with fulminant hepatitis.
METHODS: A genotype 2a replicon was constructed by isolating the consensus sequence of JFH-1, transfecting G418-selectable subgenomic transcripts into Huh7 cells, and estimating the replication efficiency.
RESULTS: The colony formation efficiency of the JFH-1 replicon was 53,200 colonies/microg RNA, significantly higher than that of the genotype 1b cell-adapted replicon, at 909 colonies/microg RNA (P < 0.05). The JFH-1 replicon RNA was transmissible to naive Huh7 cells by transfection of cellular RNA from cells containing the replicon. Sequencing of cloned replicon RNAs revealed that all but 1 had at least 1 nonsynonymous mutation. One of these mutations was shown to enhance the colony formation efficiency of the JFH-1 replicon. Furthermore, the JFH-1 replicon RNA replicated efficiently without G418 selection in a transient replication assay.
CONCLUSIONS: The genotype 2a subgenomic replicon was established in Huh7 cells and replicated efficiently with or without G418 selection. This subgenomic replicon could replicate without common amino acid mutations; however, some of the mutations found in the clones might be important in conferring higher replication phenotypes. This system provides a powerful new tool for researching HCV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14724833     DOI: 10.1053/j.gastro.2003.09.023

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  246 in total

1.  Amphipathic alpha-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B.

Authors:  Jérôme Gouttenoire; Philippe Roingeard; François Penin; Darius Moradpour
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.

Authors:  Angela M Lam; Christine Espiritu; Shalini Bansal; Holly M Micolochick Steuer; Congrong Niu; Veronique Zennou; Meg Keilman; Yuao Zhu; Shuiyun Lan; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

3.  Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.

Authors:  Tomoko Date; Takanobu Kato; Junko Kato; Hitoshi Takahashi; Kenichi Morikawa; Daisuke Akazawa; Asako Murayama; Keiko Tanaka-Kaneko; Tetsutaro Sata; Yasuhito Tanaka; Masashi Mizokami; Takaji Wakita
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

Review 4.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

5.  Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.

Authors:  Angela M Lam; Christine Espiritu; Shalini Bansal; Holly M Micolochick Steuer; Veronique Zennou; Michael J Otto; Phillip A Furman
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

6.  RNA triphosphatase DUSP11 enables exonuclease XRN-mediated restriction of hepatitis C virus.

Authors:  Rodney P Kincaid; Victor L Lam; Rachel P Chirayil; Glenn Randall; Christopher S Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

7.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.

Authors:  Yueh-Ming Loo; David M Owen; Kui Li; Andrea K Erickson; Cynthia L Johnson; Penny M Fish; D Spencer Carney; Ting Wang; Hisashi Ishida; Mitsutoshi Yoneyama; Takashi Fujita; Takeshi Saito; William M Lee; Curt H Hagedorn; Daryl T-Y Lau; Steven A Weinman; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

8.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

Authors:  Thomas Pietschmann; Artur Kaul; George Koutsoudakis; Anna Shavinskaya; Stephanie Kallis; Eike Steinmann; Karim Abid; Francesco Negro; Marlene Dreux; Francois-Loic Cosset; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Therapeutic targeting of GSK3β enhances the Nrf2 antioxidant response and confers hepatic cytoprotection in hepatitis C.

Authors:  Yongfang Jiang; Hui Bao; Yan Ge; Wei Tang; Du Cheng; Kaizhong Luo; Guozhong Gong; Rujun Gong
Journal:  Gut       Date:  2014-05-08       Impact factor: 23.059

10.  Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread.

Authors:  Naina Barretto; Bruno Sainz; Snawar Hussain; Susan L Uprichard
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.